GENinCode PLC Issue of Share Options (2521H)

TIDMGENI

RNS Number : 2521H

GENinCode PLC

22 November 2022

GENinCode Plc

("GENinCode" or the "Company")

Issue of Share Options

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease ("CVD"), announces that under its Company Share Option Scheme plan, it has granted 200,000 share options to Felix Frueh, Non-Executive Director. Felix joined the Board of GENinCode Plc earlier this year.

The share options were granted at an exercise price of 44p per share and will vest over three years.

The issue of the share options does not affect the number of shares in issue or the voting rights of GENinCode Plc. The number of shares in issue remains at 95,816,866.

PDMR Disclosure

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail on the director's share dealing.

 
 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                                    Felix Frueh 
      -------------------------------------  --------------------------------- 
 2     Reason for the notification 
      ------------------------------------------------------------------------ 
 a)    Position/status                             Non-Executive Director 
      -------------------------------------  --------------------------------- 
 b)    Initial notification                    Initial Notification 
        /Amendment 
      -------------------------------------  --------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------ 
 a)    Name                                    GENinCode plc 
      -------------------------------------  --------------------------------- 
 b)    LEI                                     213800UX6TE7K6502892 
      -------------------------------------  --------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions have 
        been conducted 
      ------------------------------------------------------------------------ 
 a)    Description of the                     Ordinary shares of 1p each 
        financial instrument, 
        type of instrument 
 
       Identification code                    ISIN: GB00BL97B504 
 
 b)    Nature of the transaction                    Issue of Options 
      -------------------------------------  --------------------------------- 
 c)    Price(s) and volume(s) 
                                              --------------  -------------- 
                                               Price(s)        Volume(s) 
                                              --------------  -------------- 
                                               44p             200,000 
                                              --------------  -------------- 
 
 d)    Aggregated information 
 
  - Aggregated volume                    200,000 
 
  - Price                                44p 
 
 e)    Date of the transaction                22 November 2022 
      -------------------------------------  --------------------------------- 
 f)    Place of the transaction               Off market 
      -------------------------------------  --------------------------------- 
 

For more information visit www.genincode.com

 
 GENinCode Plc                                        www.genincode.com or via Walbrook PR 
 Matthew Walls, CEO 
 Paul Foulger, CFO 
 
 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)          Tel: [phone] 
 Alex Price / Ben Maddison / Richard Short 
 
 Cenkos Securities Plc (Joint Broker)                             Tel: [phone] 
 Giles Balleny 
 Dale Bellis / Michael Johnson (Sales) 
 
 Walbrook PR Limited                                                 Tel: [phone] or 
 Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage               [e-mail] 
 
 

About GENinCode

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.

About Cardiovascular Disease

Cardiovascular disease (CVD) is the leading cause of death globally, taking an estimated 17.9 million lives each year. CVD is a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease and other conditions. More than four out of five CVD deaths are due to heart attacks and strokes, and one third of these deaths occur prematurely in people under 70 years of age.

The most important behavioural risk factors of heart disease and stroke are unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol. The effects of behavioural risk factors may show up in individuals as raised blood pressure, raised blood glucose, raised blood lipids, and overweight and obesity. These "intermediate risks factors" can be measured in primary care facilities and indicate an increased risk of heart attack, stroke, heart failure and other complications.

Cessation of tobacco use, reduction of salt in the diet, eating more fruit and vegetables, regular physical activity and avoiding harmful use of alcohol have been shown to reduce the risk of cardiovascular disease. Health policies that create conducive environments for making healthy choices affordable and available are essential for motivating people to adopt and sustain healthy behaviours.

Identifying those at highest risk of CVDs and ensuring they receive appropriate treatment can prevent premature deaths. Access to noncommunicable disease medicines and basic health technologies in all primary health care facilities is essential to ensure that those in need receive treatment and counselling.

CVD causes a quarter of all deaths in the UK and is the largest cause of premature mortality in deprived areas and is the single biggest area where the NHS can save lives over the next 10 years. CVD is largely preventable, through lifestyle changes and a combination of public health and NHS action on smoking and tobacco addiction, obesity, tackling alcohol misuse and food reformulation.

Genetic risk assessment enables early detection and treatment of CVD to help patients live longer , healthier lives. Too many people are still living with undetected, high-risk conditions such as high blood pressure, raised cholesterol, and atrial fibrillation (AF). Progress continues in the NHS to identify and diagnose people early and routinely knowing their 'ABC' (testing and monitoring AF, Blood pressure and Cholesterol) set out in the NHS 10 Year plan.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGZMZMDZFGZZM

(END) Dow Jones Newswires

November 22, 2022 09:07 ET (14:07 GMT)